Abstract
Summary
The neurological disease model chip is a biological simulation technology specifically used to simulate the pathogenesis and drug treatment effects of specific neurological diseases. This technology is usually implemented on a microfluidic chip or a microbial chip, and artificially cultured nerve cells or tissues are planted on the chip through tissue engineering and biotechnology means. Nervous disease model chips can be used to study a variety of neurological diseases, such as Parkinson's disease, Alzheimer's disease, epilepsy, stroke, etc. By simulating disease-related physiological and pathological processes as well as the effects of drugs on diseases, researchers can better understand the pathogenesis of neurological diseases and evaluate the efficacy and safety of potential treatments and drugs.
The global Neurological Disease Model Chip market size is projected to grow from US$ 53.6 million in 2024 to US$ 86.8 million in 2030; it is expected to grow at a CAGR of 8.4% from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Neurological Disease Model Chip Industry Forecast” looks at past sales and reviews total world Neurological Disease Model Chip sales in 2023, providing a comprehensive analysis by region and market sector of projected Neurological Disease Model Chip sales for 2024 through 2030. With Neurological Disease Model Chip sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurological Disease Model Chip industry.
This Insight Report provides a comprehensive analysis of the global Neurological Disease Model Chip landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurological Disease Model Chip portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neurological Disease Model Chip market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurological Disease Model Chip and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurological Disease Model Chip.
The neurological disease model chip market is a high-profile market segment in the biomedical field and has shown a rapid growth trend in recent years. With the deepening of neuroscience research and the continuous advancement of technology, more and more scientific research institutions and pharmaceutical companies have begun to pay attention to and invest in this field, promoting the expansion of the market scale. Neurological disease model chips are widely used in many fields such as neuroscience research, drug research and development, disease diagnosis and treatment. By simulating the structure and function of the nervous system, it can help researchers gain a deeper understanding of the pathogenesis of neurological diseases and find new treatments. In summary, the neurological disease model chip market has broad application prospects and huge market potential.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurological Disease Model Chip market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Neuron Chip
Brain Chip
Brain Organ Chip
Segmentation by Application:
Pharmaceutical R&D
Neuroscience Research
Clinical Diagnosis
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Emulate
CN Bio
TissUse
AxoSim Technologies
Nortis
Mimetas
SynVivo
Axion Biosystems
Tara Biosystems
InSphero
Hesperos
Kugelmeiers
Ascendance Biotechnology
BioIVT
BGI Genomics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Neurological Disease Model Chip market?
What factors are driving Neurological Disease Model Chip market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neurological Disease Model Chip market opportunities vary by end market size?
How does Neurological Disease Model Chip break out by Type, by Application?
The global Neurological Disease Model Chip market size is projected to grow from US$ 53.6 million in 2024 to US$ 86.8 million in 2030; it is expected to grow at a CAGR of 8.4% from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Neurological Disease Model Chip Industry Forecast” looks at past sales and reviews total world Neurological Disease Model Chip sales in 2023, providing a comprehensive analysis by region and market sector of projected Neurological Disease Model Chip sales for 2024 through 2030. With Neurological Disease Model Chip sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neurological Disease Model Chip industry.
This Insight Report provides a comprehensive analysis of the global Neurological Disease Model Chip landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurological Disease Model Chip portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neurological Disease Model Chip market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neurological Disease Model Chip and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neurological Disease Model Chip.
The neurological disease model chip market is a high-profile market segment in the biomedical field and has shown a rapid growth trend in recent years. With the deepening of neuroscience research and the continuous advancement of technology, more and more scientific research institutions and pharmaceutical companies have begun to pay attention to and invest in this field, promoting the expansion of the market scale. Neurological disease model chips are widely used in many fields such as neuroscience research, drug research and development, disease diagnosis and treatment. By simulating the structure and function of the nervous system, it can help researchers gain a deeper understanding of the pathogenesis of neurological diseases and find new treatments. In summary, the neurological disease model chip market has broad application prospects and huge market potential.
This report presents a comprehensive overview, market shares, and growth opportunities of Neurological Disease Model Chip market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Neuron Chip
Brain Chip
Brain Organ Chip
Segmentation by Application:
Pharmaceutical R&D
Neuroscience Research
Clinical Diagnosis
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Emulate
CN Bio
TissUse
AxoSim Technologies
Nortis
Mimetas
SynVivo
Axion Biosystems
Tara Biosystems
InSphero
Hesperos
Kugelmeiers
Ascendance Biotechnology
BioIVT
BGI Genomics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Neurological Disease Model Chip market?
What factors are driving Neurological Disease Model Chip market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neurological Disease Model Chip market opportunities vary by end market size?
How does Neurological Disease Model Chip break out by Type, by Application?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neurological Disease Model Chip Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Neurological Disease Model Chip by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Neurological Disease Model Chip by Country/Region, 2019, 2023 & 2030
2.2 Neurological Disease Model Chip Segment by Type
2.2.1 Neuron Chip
2.2.2 Brain Chip
2.2.3 Brain Organ Chip
2.3 Neurological Disease Model Chip Sales by Type
2.3.1 Global Neurological Disease Model Chip Sales Market Share by Type (2019-2024)
2.3.2 Global Neurological Disease Model Chip Revenue and Market Share by Type (2019-2024)
2.3.3 Global Neurological Disease Model Chip Sale Price by Type (2019-2024)
2.4 Neurological Disease Model Chip Segment by Application
2.4.1 Pharmaceutical R&D
2.4.2 Neuroscience Research
2.4.3 Clinical Diagnosis
2.5 Neurological Disease Model Chip Sales by Application
2.5.1 Global Neurological Disease Model Chip Sale Market Share by Application (2019-2024)
2.5.2 Global Neurological Disease Model Chip Revenue and Market Share by Application (2019-2024)
2.5.3 Global Neurological Disease Model Chip Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Neurological Disease Model Chip Breakdown Data by Company
3.1.1 Global Neurological Disease Model Chip Annual Sales by Company (2019-2024)
3.1.2 Global Neurological Disease Model Chip Sales Market Share by Company (2019-2024)
3.2 Global Neurological Disease Model Chip Annual Revenue by Company (2019-2024)
3.2.1 Global Neurological Disease Model Chip Revenue by Company (2019-2024)
3.2.2 Global Neurological Disease Model Chip Revenue Market Share by Company (2019-2024)
3.3 Global Neurological Disease Model Chip Sale Price by Company
3.4 Key Manufacturers Neurological Disease Model Chip Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neurological Disease Model Chip Product Location Distribution
3.4.2 Players Neurological Disease Model Chip Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Neurological Disease Model Chip by Geographic Region
4.1 World Historic Neurological Disease Model Chip Market Size by Geographic Region (2019-2024)
4.1.1 Global Neurological Disease Model Chip Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Neurological Disease Model Chip Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Neurological Disease Model Chip Market Size by Country/Region (2019-2024)
4.2.1 Global Neurological Disease Model Chip Annual Sales by Country/Region (2019-2024)
4.2.2 Global Neurological Disease Model Chip Annual Revenue by Country/Region (2019-2024)
4.3 Americas Neurological Disease Model Chip Sales Growth
4.4 APAC Neurological Disease Model Chip Sales Growth
4.5 Europe Neurological Disease Model Chip Sales Growth
4.6 Middle East & Africa Neurological Disease Model Chip Sales Growth
5 Americas
5.1 Americas Neurological Disease Model Chip Sales by Country
5.1.1 Americas Neurological Disease Model Chip Sales by Country (2019-2024)
5.1.2 Americas Neurological Disease Model Chip Revenue by Country (2019-2024)
5.2 Americas Neurological Disease Model Chip Sales by Type (2019-2024)
5.3 Americas Neurological Disease Model Chip Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurological Disease Model Chip Sales by Region
6.1.1 APAC Neurological Disease Model Chip Sales by Region (2019-2024)
6.1.2 APAC Neurological Disease Model Chip Revenue by Region (2019-2024)
6.2 APAC Neurological Disease Model Chip Sales by Type (2019-2024)
6.3 APAC Neurological Disease Model Chip Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Neurological Disease Model Chip by Country
7.1.1 Europe Neurological Disease Model Chip Sales by Country (2019-2024)
7.1.2 Europe Neurological Disease Model Chip Revenue by Country (2019-2024)
7.2 Europe Neurological Disease Model Chip Sales by Type (2019-2024)
7.3 Europe Neurological Disease Model Chip Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neurological Disease Model Chip by Country
8.1.1 Middle East & Africa Neurological Disease Model Chip Sales by Country (2019-2024)
8.1.2 Middle East & Africa Neurological Disease Model Chip Revenue by Country (2019-2024)
8.2 Middle East & Africa Neurological Disease Model Chip Sales by Type (2019-2024)
8.3 Middle East & Africa Neurological Disease Model Chip Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neurological Disease Model Chip
10.3 Manufacturing Process Analysis of Neurological Disease Model Chip
10.4 Industry Chain Structure of Neurological Disease Model Chip
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neurological Disease Model Chip Distributors
11.3 Neurological Disease Model Chip Customer
12 World Forecast Review for Neurological Disease Model Chip by Geographic Region
12.1 Global Neurological Disease Model Chip Market Size Forecast by Region
12.1.1 Global Neurological Disease Model Chip Forecast by Region (2025-2030)
12.1.2 Global Neurological Disease Model Chip Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Neurological Disease Model Chip Forecast by Type (2025-2030)
12.7 Global Neurological Disease Model Chip Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Emulate
13.1.1 Emulate Company Information
13.1.2 Emulate Neurological Disease Model Chip Product Portfolios and Specifications
13.1.3 Emulate Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Emulate Main Business Overview
13.1.5 Emulate Latest Developments
13.2 CN Bio
13.2.1 CN Bio Company Information
13.2.2 CN Bio Neurological Disease Model Chip Product Portfolios and Specifications
13.2.3 CN Bio Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 CN Bio Main Business Overview
13.2.5 CN Bio Latest Developments
13.3 TissUse
13.3.1 TissUse Company Information
13.3.2 TissUse Neurological Disease Model Chip Product Portfolios and Specifications
13.3.3 TissUse Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 TissUse Main Business Overview
13.3.5 TissUse Latest Developments
13.4 AxoSim Technologies
13.4.1 AxoSim Technologies Company Information
13.4.2 AxoSim Technologies Neurological Disease Model Chip Product Portfolios and Specifications
13.4.3 AxoSim Technologies Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 AxoSim Technologies Main Business Overview
13.4.5 AxoSim Technologies Latest Developments
13.5 Nortis
13.5.1 Nortis Company Information
13.5.2 Nortis Neurological Disease Model Chip Product Portfolios and Specifications
13.5.3 Nortis Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Nortis Main Business Overview
13.5.5 Nortis Latest Developments
13.6 Mimetas
13.6.1 Mimetas Company Information
13.6.2 Mimetas Neurological Disease Model Chip Product Portfolios and Specifications
13.6.3 Mimetas Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Mimetas Main Business Overview
13.6.5 Mimetas Latest Developments
13.7 SynVivo
13.7.1 SynVivo Company Information
13.7.2 SynVivo Neurological Disease Model Chip Product Portfolios and Specifications
13.7.3 SynVivo Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 SynVivo Main Business Overview
13.7.5 SynVivo Latest Developments
13.8 Axion Biosystems
13.8.1 Axion Biosystems Company Information
13.8.2 Axion Biosystems Neurological Disease Model Chip Product Portfolios and Specifications
13.8.3 Axion Biosystems Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Axion Biosystems Main Business Overview
13.8.5 Axion Biosystems Latest Developments
13.9 Tara Biosystems
13.9.1 Tara Biosystems Company Information
13.9.2 Tara Biosystems Neurological Disease Model Chip Product Portfolios and Specifications
13.9.3 Tara Biosystems Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Tara Biosystems Main Business Overview
13.9.5 Tara Biosystems Latest Developments
13.10 InSphero
13.10.1 InSphero Company Information
13.10.2 InSphero Neurological Disease Model Chip Product Portfolios and Specifications
13.10.3 InSphero Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 InSphero Main Business Overview
13.10.5 InSphero Latest Developments
13.11 Hesperos
13.11.1 Hesperos Company Information
13.11.2 Hesperos Neurological Disease Model Chip Product Portfolios and Specifications
13.11.3 Hesperos Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Hesperos Main Business Overview
13.11.5 Hesperos Latest Developments
13.12 Kugelmeiers
13.12.1 Kugelmeiers Company Information
13.12.2 Kugelmeiers Neurological Disease Model Chip Product Portfolios and Specifications
13.12.3 Kugelmeiers Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Kugelmeiers Main Business Overview
13.12.5 Kugelmeiers Latest Developments
13.13 Ascendance Biotechnology
13.13.1 Ascendance Biotechnology Company Information
13.13.2 Ascendance Biotechnology Neurological Disease Model Chip Product Portfolios and Specifications
13.13.3 Ascendance Biotechnology Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 Ascendance Biotechnology Main Business Overview
13.13.5 Ascendance Biotechnology Latest Developments
13.14 BioIVT
13.14.1 BioIVT Company Information
13.14.2 BioIVT Neurological Disease Model Chip Product Portfolios and Specifications
13.14.3 BioIVT Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 BioIVT Main Business Overview
13.14.5 BioIVT Latest Developments
13.15 BGI Genomics
13.15.1 BGI Genomics Company Information
13.15.2 BGI Genomics Neurological Disease Model Chip Product Portfolios and Specifications
13.15.3 BGI Genomics Neurological Disease Model Chip Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 BGI Genomics Main Business Overview
13.15.5 BGI Genomics Latest Developments
14 Research Findings and Conclusion